Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic Liabilities-Reference-Cited by-同舟云学术

Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic Liabilities

Published:2016-03-30 Issue:8 Volume:11 Page:850-861
ISSN:1860-7179
Container-title:ChemMedChem
language:en
Short-container-title:ChemMedChem

Author:

Ali Ahmed M.¹²,Gómez-Biagi Rodolfo F.¹,Rosa David A.¹,Lai Ping-Shan¹,Heaton William L.³,Park Ji Sung¹,Eiring Anna M.³,Vellore Nadeem A.³,de Araujo Elvin D.¹,Ball Dan P.¹,Shouksmith Andrew E.¹,Patel Ami B.³,Deininger Michael W.³,O'Hare Thomas³,Gunning Patrick T.¹

Affiliation:

1. Department of Chemistry; University of Toronto Mississauga; Mississauga ON L5L 1C6 Canada

2. Department of Medicinal Chemistry; Faculty of Pharmacy; Assiut University; Assiut 71515 Egypt

3. Huntsman Cancer Institute; Division of Hematology and Hematologic Malignancies; University of Utah; Salt Lake City UT 84112 USA

Funder

Leukemia & Lymphoma Society

Leukemia and Lymphoma Society for Canada

Canadian Institutes for Health Research

National Cancer Institute (NCI)

National Institutes of Health (NIH)

Publisher

Wiley

Subject

Organic Chemistry,General Pharmacology, Toxicology and Pharmaceutics,Molecular Medicine,Drug Discovery,Biochemistry,Pharmacology

Reference54 articles.

1. Targeting the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

2. Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis

3. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

4. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of YSR734: A Covalent HDAC Inhibitor with Cellular Activity in Acute Myeloid Leukemia and Duchenne Muscular Dystrophy;Journal of Medicinal Chemistry;2023-12-07

2. The war on hTG2: warhead optimization in small molecule human tissue transglutaminase inhibitors;RSC Medicinal Chemistry;2023

3. STAT Protein Thermal Shift Assays to Monitor Protein‐Inhibitor Interactions;ChemBioChem;2022-07-05

4. Discovery of HDAC6-Selective Inhibitor NN-390 with in Vitro Efficacy in Group 3 Medulloblastoma;Journal of Medicinal Chemistry;2022-02-04

5. Unique Molecular Interaction with the Histone Deacetylase 6 Catalytic Tunnel: Crystallographic and Biological Characterization of a Model Chemotype;Journal of Medicinal Chemistry;2021-02-12